This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.RE Coleman . Skeletal complications of malignancy. Cancer 1997; 80: 1588–1594.
2.RE Coleman . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s–6249s.
3.RE Coleman . Bisphosphonates: clinical experience. Oncologist 2004; 9 (Suppl 4): 14–27.
4.T Yoneda . Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000; 5: 75–81.
5.JJ Yin , CB Pollock , K Kelly . Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15: 57–62.
6.RJ Thomas , TA Guise , JJ Yin , . Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451–4458.
7.GR Mundy . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.
8.GN Hortobagyi , RL Theriault , L Porter , . Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785–1791.
9.RE Coleman . Bisphosphonates in breast cancer. Ann Oncol 2005; 16: 687–695.
11.LS Rosen , DH Gordon , W Dugan Jr., . Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36–43.
12.JR Green . Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 3–13.
13.D Santini , U Vespasiani Gentilucci , B Vincenzi , . The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14: 1468–1476.
15.S Magnetto , S Boissier , PD Delmas , P Clezardin . Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263–269.
16.SP Jagdev , RE Coleman , CM Shipman , HA Rostami , PI Croucher . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–1134.
17.HL Neville-Webbe , A Rostami-Hodjegan , CA Evans , RE Coleman , I Holen . Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113: 364–371.
18.HL Neville Webbe , CA Evans , RE Coleman , I Holen . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92–103.
20.IJ Diel , EF Solomeyer , SD Costa , . Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–363.
21.S Braun , FD Vogel , B Naume , . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793–802.
23.T Powles , S Paterson , JA Kanis , . Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219–3224.
24.T Powles , A Paterson , E McCloskey , . Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer (ISRCTN83688026). Breast Cancer Res 2006; 8: R13.
26.T Saarto , L Vehmanen , P Virkkunen , C Blomqvist . Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650–656.
27.BE Hillner , JN Ingle , RT Chlebowski , . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–4057.
30.K Mystakidou , E Katsouda , E Parpa , . Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195–201.
31.AH Paterson . The role of bisphosphonates in early breast cancer. Oncologist 2006; 11 (Suppl 1): 13–19.
32.SL Ruggiero , B Mehrotra , TJ Rosenberg , SL Engroff . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527–534.
33.AI Zavras , S Zhu . Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006; 64: 917–923.
35.CA Migliorati , J Casiglia , J Epstein , . Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658–1668.